A randomized, balanced, two-treatment, two-sequence, single oral dose, two stage crossover adaptative bioequivalence study of Rifaximin 200 mg film-coated tablets (Antibiotice SA) vs. Normix® 200 mg, film- coated tablets (Alfasigma S.P.A) in healthy subjects under fed conditions

This study is like a 'twin test' for two versions of a 200mg tablet containing a medicine called rifaximin. Rifaximin is used for certain gut problems. One tablet is a well-known version called Normix®, and the other is a new version made by a company called Antibiotice SA. The main purpose of this research is to see if the new tablet works in exactly the same way as Normix® once it's inside your body. Think of it like comparing two different brands of bottled water – you want to make sure they're both equally good at hydrating you, even if they come in different bottles.

To do this, healthy volunteers will take a single dose of each tablet at different times. They'll always take the tablet after they've had a meal. By doing this, the researchers can measure how much of the medicine gets into the bloodstream and how quickly. This comparison is really important because it helps ensure that new versions of medicines (like this one from Antibiotice SA) behave in the same way as established ones. If they are 'bioequivalent,' it means they can be used interchangeably, giving doctors and patients more options while keeping treatments consistently effective and safe.

This kind of study is a standard part of how new medicines are developed and approved. It's not about testing if the medicine works to treat a disease, but rather making sure that different manufactured versions of the same medicine are just as good as each other. It helps regulators confirm that if you're prescribed rifaximin, you'll get the same effect whether you receive the original or a generic equivalent.